Sharfstein On Zohydro: FDA Should Require Opioid Abuse Deterrent Standards
This article was originally published in The Pink Sheet Daily
Executive Summary
Former FDA Principal Deputy Commissioner Joshua Sharfstein suggests FDA create a pathway for development of new products for simultaneous treatment of chronic pain and opioid disorder.